191 related articles for article (PubMed ID: 31431054)
1. Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function.
Nagasu H; Sogawa Y; Kidokoro K; Itano S; Yamamoto T; Satoh M; Sasaki T; Suzuki T; Yamamoto M; Wigley WC; Proksch JW; Meyer CJ; Kashihara N
FASEB J; 2019 Nov; 33(11):12253-12263. PubMed ID: 31431054
[TBL] [Abstract][Full Text] [Related]
2. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction.
Sharma A; Rizky L; Stefanovic N; Tate M; Ritchie RH; Ward KW; de Haan JB
Cardiovasc Diabetol; 2017 Mar; 16(1):33. PubMed ID: 28253885
[TBL] [Abstract][Full Text] [Related]
3. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Shelkovnikov S; Farzaneh SH; Khazaeli M; Meyer CJ
Redox Biol; 2013; 1(1):527-31. PubMed ID: 24363993
[TBL] [Abstract][Full Text] [Related]
4. The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling.
Bubb KJ; Kok C; Tang O; Rasko NB; Birgisdottir AB; Hansen T; Ritchie R; Bhindi R; Reisman SA; Meyer C; Ward K; Karimi Galougahi K; Figtree GA
Free Radic Biol Med; 2017 Jul; 108():585-594. PubMed ID: 28438659
[TBL] [Abstract][Full Text] [Related]
5. Dihydro-CDDO-trifluoroethyl amide suppresses inflammatory responses in macrophages via activation of Nrf2.
Li B; Abdalrahman A; Lai Y; Janicki JS; Ward KW; Meyer CJ; Wang XL; Tang D; Cui T
Biochem Biophys Res Commun; 2014 Feb; 444(4):555-61. PubMed ID: 24486487
[TBL] [Abstract][Full Text] [Related]
6. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease.
Tan SM; Sharma A; Stefanovic N; Yuen DY; Karagiannis TC; Meyer C; Ward KW; Cooper ME; de Haan JB
Diabetes; 2014 Sep; 63(9):3091-103. PubMed ID: 24740568
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease.
Vaziri ND; Liu S; Farzaneh SH; Nazertehrani S; Khazaeli M; Zhao YY
Free Radic Biol Med; 2015 Sep; 86():374-81. PubMed ID: 25930007
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulation attenuates proteinuria-induced renal tubular damage by modulating mitochondrial oxidative status.
Nishi Y; Satoh M; Nagasu H; Kadoya H; Ihoriya C; Kidokoro K; Sasaki T; Kashihara N
Kidney Int; 2013 Apr; 83(4):662-73. PubMed ID: 23344476
[TBL] [Abstract][Full Text] [Related]
9. Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.
Ichikawa T; Li J; Meyer CJ; Janicki JS; Hannink M; Cui T
PLoS One; 2009 Dec; 4(12):e8391. PubMed ID: 20027226
[TBL] [Abstract][Full Text] [Related]
10. A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy.
Deliyanti D; Lee JY; Petratos S; Meyer CJ; Ward KW; Wilkinson-Berka JL; de Haan JB
Clin Sci (Lond); 2016 Aug; 130(15):1375-87. PubMed ID: 27005782
[TBL] [Abstract][Full Text] [Related]
11. Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium.
Szczesny-Malysiak E; Stojak M; Campagna R; Grosicki M; Jamrozik M; Kaczara P; Chlopicki S
Oxid Med Cell Longev; 2020; 2020():4678252. PubMed ID: 33123312
[TBL] [Abstract][Full Text] [Related]
12. The effect of Nrf2 pathway activation on human pancreatic islet cells.
Masuda Y; Vaziri ND; Li S; Le A; Hajighasemi-Ossareh M; Robles L; Foster CE; Stamos MJ; Al-Abodullah I; Ricordi C; Ichii H
PLoS One; 2015; 10(6):e0131012. PubMed ID: 26110640
[TBL] [Abstract][Full Text] [Related]
13. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Khazaeli M; Yuan J; Meyer CJ
Xenobiotica; 2014 Jun; 44(6):570-8. PubMed ID: 24195589
[TBL] [Abstract][Full Text] [Related]
14. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).
Impellizzeri D; Esposito E; Attley J; Cuzzocrea S
Pharmacol Res; 2014 Mar; 81():91-102. PubMed ID: 24602801
[TBL] [Abstract][Full Text] [Related]
15. Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2.
Xing Y; Niu T; Wang W; Li J; Li S; Janicki JS; Ruiz S; Meyer CJ; Wang XL; Tang D; Zhao Y; Cui T
PLoS One; 2012; 7(9):e44899. PubMed ID: 23028668
[TBL] [Abstract][Full Text] [Related]
16. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.
Zoja C; Corna D; Nava V; Locatelli M; Abbate M; Gaspari F; Carrara F; Sangalli F; Remuzzi G; Benigni A
Am J Physiol Renal Physiol; 2013 Mar; 304(6):F808-19. PubMed ID: 23136004
[TBL] [Abstract][Full Text] [Related]
17. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney.
Reisman SA; Chertow GM; Hebbar S; Vaziri ND; Ward KW; Meyer CJ
J Am Soc Nephrol; 2012 Oct; 23(10):1663-73. PubMed ID: 22859857
[TBL] [Abstract][Full Text] [Related]
18. NRF2 in kidney physiology and disease.
Bondi CD; Hartman HL; Tan RJ
Physiol Rep; 2024 Mar; 12(5):e15961. PubMed ID: 38418382
[TBL] [Abstract][Full Text] [Related]
19. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy.
Deliyanti D; Alrashdi SF; Tan SM; Meyer C; Ward KW; de Haan JB; Wilkinson-Berka JL
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):815-825. PubMed ID: 29411009
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure.
Tian C; Gao L; Zhang A; Hackfort BT; Zucker IH
J Pharmacol Exp Ther; 2019 Dec; 371(3):642-651. PubMed ID: 31601682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
